# Purespring Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/purespring-therapeutics

- Industry: Biotechnology
- Headquarters: London, UK
- Website: www.purespringtx.com/
- Total disclosed funding: $165M
- Latest round: Series B (Oct 9, 2024)
- Investors on record: 5

## About

Founded in 2020 and based in London, UK, Purespring Therapeutics Limited, formerly known as SYNCONA COLLABORATION (S) LIMITED, operates as a provider of gene therapies targeting podocytes to healthcare institutions and medical researchers working on kidney disease treatments. In October 2024, Purespring Therapeutics Limited raised GBP 80 million in series B funding led by Sofinnova Partners, with participation from Syncona Limited, Gilde Healthcare Partners, Forbion, and British Patient Capital. Purespring Therapeutics offers gene therapy treatments targeting podocytes for glomerular kidney diseases. Moreover, the firm's pipeline includes PS-002 for IgA nephropathy, therapies for monogenic podocyte disorders, and glomerular basal membrane deficiencies. Additionally, the company also develops platforms for renal gene therapies and collaborates on kidney disease research.

## Funding rounds

- Series B, Oct 9, 2024, $105M — Sofinnova Partners, Gilde Healthcare, Forbion, Syncona, British Patient Capital
- Series A, Nov 19, 2020, $60M — Syncona

## Investors

- Syncona (https://capitalatlas.ai/funds/syncona) — Series A, Series B
- Sofinnova Partners (https://capitalatlas.ai/funds/sofinnova-partners) — Series B
- Gilde Healthcare (https://capitalatlas.ai/funds/gilde-healthcare) — Series B
- Forbion (https://capitalatlas.ai/funds/forbion) — Series B
- British Patient Capital — Series B